Patients in the intensive care unit (ICU) have many risk factors for resistant pathogens such as prolonged length of stay, frequent and broad-spectrum antimicrobial therapy, presence of foreign materials, and proximity with other patients. However, of the risk factors associated with acquisition of resistant pathogens, inappropriate use of antimicrobial agents has been the most implicated. Thus, many health care institutions have adopted antimicrobial stewardship programs (ASPs) as a mechanism to ensure more appropriate antimicrobial use. ASPs can have a significant impact in the ICU, leading to improved antimicrobial use and resistance patterns and decreased infection rates and costs, due to the inherent nature of infections encountered and high and often inappropriate antibiotic utilization in this setting. However, certain challenges exist for ASPs in the ICU including issues with infrastructure and personnel, information technology, the core ASP strategy, patient-specific factors, conversion of intravenous to oral therapy, and dose optimization. The combination of comprehensive infection control (IC) and effective antimicrobial stewardship can prevent the emergence of resistance among microorganisms and may decrease the negative consequences associated with antimicrobial misuse.
DellitTHOwensRCMcGowanJEJr. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159–177.
3.
OwensRCJr. Antimicrobial stewardship: concepts and strategies in the 21st century. Diagn Microbiol Infect Dis. 2008;61(1):110–128.
4.
ChandrasekarPHKruseJAMathewsMF. Nosocomial infection among patients in different types of intensive care units at a city hospital. Crit Care Med. 1986;14(5):508–510.
5.
WeberDJRaaschRRutalaWA. Nosocomial infections in the ICU: the growing importance of antibiotic-resistant pathogens. Chest. 1999;115(3 suppl):34S–41S.
6.
JonesMEDraghiDCThornsberryC. Emerging resistance among bacterial pathogens in the intensive care unit—a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob. 2004;3,14.
7.
KaramGHHeffnerJE. Emerging issues in antibiotic resistance in blood-borne infections. Am J Respir Crit Care Med. 2000;162(5):1610–1616.
National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32(8):470–485.
10.
RehmSJBartlettJG. Challenges in the management of serious infections. Clin Infect Dis. 2006;42(suppl 2):S63–S64.
11.
VollesDFBrananTN. Antibiotics in the intensive care unit: focus on agents for resistant pathogens. Emerg Med Clin North Am. 2008;26(3):813–834, x.
12.
BoucherHWTalbotGHBradleyJS. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12.
13.
MadaniNRosenthalVDDendaneT. Health-care associated infections rates, length of stay, and bacterial resistance in an intensive care unit of Morocco: findings of the International Nosocomial Infection Control Consortium (INICC). Int Arch Med. 2009;2(1):29.
14.
OwensRCJrFraserGLStogsdillP. Antimicrobial stewardship programs as a means to optimize antimicrobial use. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2004;24(7):896–908.
15.
RosenthalVDMakiDGMehtaA. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control. 2008;36(9):627–637.
16.
CarmeliYEliopoulosGMozaffariE. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med. 2002;162(19):2223–2228.
17.
CarmeliYTroilletNKarchmerAW. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med. 1999;159(10):1127–1132.
18.
CosgroveSEKayeKSEliopoulousGM. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med. 2002;162(2):185–190.
19.
CosgroveSESakoulasGPerencevichEN. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36(1):53–59.
20.
EngemannJJCarmeliYCosgroveSE. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003;36(5):592–598.
21.
CosgroveSE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42(suppl 2):S82–S89.
22.
LawrenceKLKollefMH. Antimicrobial stewardship in the intensive care unit: advances and obstacles. Am J Respir Crit Care Med. 2009;179(6):434–438.
23.
LevySB. The 2000 Garrod lecture. Factors impacting on the problem of antibiotic resistance. J Antimicrob Chemother. 2002;49(1):25–30.
24.
SafdarNBradleyEA. The risk of infection after nasal colonization with Staphylococcus aureus. Am J Med. 2008;121(4):310–315.
25.
JohnsonJKSmithGLeeMS. The role of patient-to-patient transmission in the acquisition of imipenem-resistant Pseudomonas aeruginosa colonization in the intensive care unit. J Infect Dis. 2009;200(6):900–905.
26.
ErbayAColpanABodurH. Evaluation of antibiotic use in a hospital with an antibiotic restriction policy. Int J Antimicrob Agents. 2003;21(4):308–312.
27.
GonzalesRMaloneDCMaselliJH. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis. 2001;33(6):757–762.
28.
JohnJF. Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis. 1997;24(3):471–485.
29.
ErlandssonMBurmanLGCarsO. Prescription of antibiotic agents in Swedish intensive care units is empiric and precise. Scand J Infect Dis. 2007;39(1):63–69.
30.
WarrenMMGibbAPWalshTS. Antibiotic prescription practice in an intensive care unit using twice-weekly collection of screening specimens: a prospective audit in a large UK teaching hospital. J Hosp Infect. 2005;59(2):90–95.
31.
Alvarez-LermaF. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med. 1996;22(5):387–394.
32.
IbrahimEHShermanGWardS. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000;118(1):146–155.
33.
KollefMHShermanGWardS. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115(2):462–474.
34.
SpellbergBPowersJHBrassEP. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis. 2004;38(9):1279–1286.
35.
Centers for Medicare and Medicaid Services. QualityNet. http://www.qualitynet.org. Accessed August 20, 2009
36.
HermsenEDSmith ShullSPuumalaSE. Improvement in prescribing habits and economic outcomes associated with the introduction of a standardized approach for surgical antimicrobial prophylaxis. Infect Control Hosp Epidemiol. 2008;29(5):457–461.
37.
AnsariFGrayKNathwaniD. Outcomes of an intervention to improve hospital antibiotic prescribing: interrupted time series with segmented regression analysis. J Antimicrob Chemother. 2003;52(5):842–848.
38.
CarlingPFungTKillionA. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003;24(9):699–706.
39.
LaRoccoA. Concurrent antibiotic review programs—a role for infectious diseases specialists at small community hospitals. Clin Infect Dis. 2003;37(5):742–743.
40.
RuttimannSKeckBHartmeierC. Long-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated teaching hospital. Clin Infect Dis. 2004;38(3):348–356.
41.
QualeJLandmanDSaurinaG. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis. 1996;23(5):1020–1025.
42.
BradleySJWilsonALAllenMC. The control of hyperendemic glycopeptide-resistant Enterococcus spp. On a haematology unit by changing antibiotic usage. J Antimicrob Chemother. 1999;43(2):261–266.
43.
DahmsRAJohnsonEMStatzCL. Third-generation cephalosporins and vancomycin as risk factors for postoperative vancomycin-resistant enterococcus infection. Arch Surg. 1998;133(12):1343–1346.
44.
TornieporthNGRobertsRBJohnJ. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis. 1996;23(4):767–772.
45.
RahalJJUrbanCHornD. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA. 1998;280(14):1233–1237.
46.
MartinCOfotokunIRappR. Results of an antimicrobial control program at a university hospital. Am J Health Syst Pharm. 2005;62(7):732–738.
47.
GentryCAGreenfieldRASlaterLN. Outcomes of an antimicrobial control program in a teaching hospital. Am J Health Syst Pharm. 2000;57(3):268–274.
48.
NgCKWuTCChanWM. Clinical and economic impact of an antibiotics stewardship programme in a regional hospital in Hong Kong. Qual Saf Health Care. 2008;17(5):387–392.
49.
BantarCSartoriBVescoE. A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, bacterial resistance. Clin Infect Dis. 2003;37(2):180–186.
50.
FraserGLStogsdillPDickensJDJr. Antibiotic optimization. An evaluation of patient safety and economic outcomes. Arch Intern Med. 1997;157(15):1689–1694.
51.
GrossRMorganASKinkyDE. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis. 2001;33(3):289–295.
52.
SrinivasanASongXRichardsA. A survey of knowledge, attitudes, beliefs of house staff physicians from various specialties concerning antimicrobial use and resistance. Arch Intern Med. 2004;164(13):1451–1456.
53.
SunenshineRHLiedtkeLAJerniganDB. Role of infectious diseases consultants in management of antimicrobial use in hospitals. Clin Infect Dis. 2004;38(7):934–938.
54.
FitzpatrickFRocheFCunneyR. Challenges of implementing national guidelines for the control and prevention of methicillin-resistant Staphylococcus aureus colonization or infection in acute care hospitals in the Republic of Ireland. Infect Control Hosp Epidemiol. 2009;30(3):277–281.
55.
WhiteAC. Atmar RL, Wilson J, et al. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, clinical outcomes. Clin Infect Dis. 1997;25(2):230–239.
56.
PeaFVialeP. Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock—does the dose matter?. Crit Care. 2009;13(3):214.
57.
EndimianiAPatersonDL. Optimizing therapy for infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases. Semin Respir Crit Care Med. 2007;28(6):646–655.
58.
KasiakouSKLawrenceKRChoulisN. Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters. Drugs. 2005;65(17):2499–2511.
59.
NicolauDPFreemanCDBelliveauPP. Experience with a once-daily aminoglycoside program administered to 2, 184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650–655.
60.
AmbrosePGBhavnaniSMRubinoCM. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis. 2007;44(1):79–86.
61.
AngusBJSmithMDSuputtamongkolY. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol. 2000;50(2):184–191.
62.
BenkoASCappellettyDMKruseJA. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother. 1996;40(3):691–695.
63.
BurgessDSHastingsRWHardinTC. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Ther. 2000;22(1):66–75.
64.
FeldRRachlisATuffnellPG. Empiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole. Arch Intern Med. 1984;144(5):1005–1010.
65.
LodiseTP. Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44(3):357–363.
66.
YoungRJLipmanJGinT. Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother. 1997;40(2):269–273.
67.
HotaSHirjiZStocktonK. Outbreak of multidrug-resistant Pseudomonas aeruginosa colonization and infection secondary to imperfect intensive care unit room design. Infect Control Hosp Epidemiol. 2009;30(1):25–33.
68.
ChangHLTangCHHsuYM. Nosocomial outbreak of infection with multidrug-resistant Acinetobacter baumannii in a medical center in Taiwan. Infect Control Hosp Epidemiol. 2009;30(1):34–38.
69.
CarlingPCVon BeherenSKimP. Intensive care unit environmental cleaning: an evaluation in sixteen hospitals using a novel assessment tool. J Hosp Infect. 2008;68(1):39–44.
